Download PDF

1. Company Snapshot

1.a. Company Description

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States.The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components.


The company is based in Redwood City, California.

Show Full description

1.b. Last Insights on BTCY

Here is a 90-word analysis of the positive drivers behind Biotricity, Inc.'s recent stock performance: Biotricity's recent strong performance is driven by its achievement of cash flow breakeven and record revenue growth of 11% in Q3 2025. The company delivered record margins, revenues, and cash flows, with 21.7% year-over-year sales growth. Additionally, Biotricity achieved positive free cash flow, a major milestone towards profitability. The company has also produced its largest inventory in history to meet accelerated demand, and partnered with B-Secur to launch a comprehensive device-neutral ambulatory cardiac monitoring platform, further enhancing its growth prospects.

1.c. Company Highlights

2. Biotricity's Q3 FY2026 Earnings: A Step Closer to Profitability

Biotricity reported revenue of $4 million for the third quarter of fiscal 2026, marking a 10.2% increase from $3.6 million in the prior year quarter. Technology fees accounted for 91.2% of total revenue, underscoring the company's reliance on its technology-driven healthcare solutions. Gross profit was $3.3 million, up 17.6% from $2.8 million, with a gross profit percentage of 81.5%, a significant improvement of 516 basis points. The company's EBITDA was $280,000, or $0.01 per share, and it achieved a positive operating income of $441,000. The net loss attributable to common stockholders was $1.1 million, or $0.042 per share, which is an improvement from the expected loss of $0.08 per share. The actual EPS came out at '-0.04161' relative to estimates.

Publication Date: Feb -25

📋 Highlights
  • Revenue Growth:: $4 million (10.2% YoY increase) driven by 91.2% contribution from technology fees.
  • Gross Profit Expansion:: $3.3 million (17.6% YoY growth) with a 81.5% margin, up 516 basis points.
  • EBITDA & Operating Income:: $280,000 EBITDA ($0.01/share) and $441,000 operating income, reflecting 3 consecutive quarters of positive performance.
  • Operating Expense Reduction:: $2.8 million (4.2% decline) led by 8.2% drop in SG&A costs.
  • Digital Ecosystem Growth:: 44,000 app users, 2,500+ providers supporting 400,000 patients annually, with plans for profitability in 2026.

Operational Highlights

The company continues to execute its strategy, with three consecutive quarters of positive net operating income and EBITDA. Biotricity's digital ecosystem has grown significantly, with 44,000 digital health app users and over 2,500 providers supporting 400,000 patients annually. The company expects continued strong adoption of its Biocore Pro device and expansion of its cardiac AI cloud platform. As the company's management stated, "we are confident in our ability to drive value for shareholders and improve patient outcomes globally, with plans to turn profitable this year."

Valuation and Growth Prospects

Analysts estimate next year's revenue growth at 15.3%, indicating a positive outlook for the company's future performance. With a P/S Ratio of 0.52, the market appears to be cautiously optimistic about Biotricity's prospects. However, the EV/EBITDA ratio of 130.08 suggests that the company's valuation is still heavily dependent on its future growth potential. As Biotricity continues to execute its strategy and move closer to profitability, investors will be watching closely to see if the company can deliver on its promises.

Key Metrics

Biotricity's current valuation metrics, including a ROE of 12.85% and a Net Debt / EBITDA ratio of 100.31, provide insight into the company's financial health and leverage. While the company's path to profitability is promising, its high EV/EBITDA ratio and negative Free Cash Flow Yield of -13.8% highlight the challenges it still faces in achieving sustained profitability.

3. NewsRoom

Card image cap

Financial Survey: 10x Genomics (NASDAQ:TXG) and Biotricity (OTCMKTS:BTCY)

Feb -20

Source: defenseworld.net

Card image cap

Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript

Feb -11

Source: seekingalpha.com

Card image cap

Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

Feb -11

Source: globenewswire.com

Card image cap

Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

Feb -05

Source: globenewswire.com

Card image cap

Comparing Biotricity (OTCMKTS:BTCY) & 111 (NASDAQ:YI)

Jan -12

Source: defenseworld.net

Card image cap

Head-To-Head Analysis: Zepp Health (NYSE:ZEPP) versus Biotricity (OTCMKTS:BTCY)

Dec -30

Source: defenseworld.net

Card image cap

3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run

Dec -23

Source: zacks.com

Card image cap

Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript

Nov -14

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.55%)

6. Segments

Technology Fees

Expected Growth: 14.07%

Biotricity's 14.07% growth in Technology Fees is driven by increasing adoption of its remote patient monitoring solutions, expansion into new healthcare verticals, and growing demand for telemedicine services. Additionally, the company's investments in AI-powered analytics and IoT-enabled devices have enhanced its value proposition, leading to higher revenue from technology licensing and subscription fees.

Device

Expected Growth: 8.9%

Biotricity's device growth is driven by increasing demand for remote patient monitoring, advancements in AI-powered diagnostics, and expanding healthcare access. The company's focus on cardiovascular and respiratory disease management, coupled with its innovative technology and strategic partnerships, have contributed to its 8.9% growth.

7. Detailed Products

Bioflux

A mobile cardiac telemetry device that provides real-time monitoring of a patient's heart rhythm

Biotres

A suite of software solutions for remote patient monitoring and data analytics

Biocare

A range of wearable devices for remote patient monitoring, including ECG, blood glucose, and blood pressure monitoring

Biotricity Wellness

A comprehensive wellness program that includes health coaching, nutrition planning, and stress management

8. Biotricity, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Biotricity, Inc. faces moderate threat from substitutes due to the presence of alternative medical devices and services.

Bargaining Power Of Customers

Customers have limited bargaining power due to the specialized nature of Biotricity's products and services.

Bargaining Power Of Suppliers

Suppliers have moderate bargaining power due to the availability of alternative suppliers and the company's dependence on a few key suppliers.

Threat Of New Entrants

The medical device industry is highly competitive, and new entrants can easily enter the market, posing a significant threat to Biotricity, Inc.

Intensity Of Rivalry

The medical device industry is highly competitive, and rivalry among existing players is intense, posing a significant threat to Biotricity, Inc.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight -6532.53%
Debt Cost 11.70%
Equity Weight 6632.53%
Equity Cost 11.70%
WACC 11.70%
Leverage -98.49%

11. Quality Control: Biotricity, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Biotricity

A-Score: 5.2/10

Value: 9.6

Growth: 5.6

Quality: 6.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Tactile Systems Technology

A-Score: 4.9/10

Value: 3.1

Growth: 7.7

Quality: 7.1

Yield: 0.0

Momentum: 9.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Electromed

A-Score: 4.0/10

Value: 1.9

Growth: 8.8

Quality: 7.4

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Talis Biomedical

A-Score: 3.9/10

Value: 8.2

Growth: 4.6

Quality: 4.4

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Quipt Home Medical

A-Score: 3.8/10

Value: 8.2

Growth: 6.3

Quality: 3.8

Yield: 0.0

Momentum: 3.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Myomo

A-Score: 3.1/10

Value: 8.5

Growth: 4.7

Quality: 4.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.23$

Current Price

0.23$

Potential

-0.00%

Expected Cash-Flows